News
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...
Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.
Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...
By Nancy Lapid (Reuters) -Bariatric surgeries led to about five-times more weight loss than weekly injections of popular ...
Hair loss is becoming a concern for some individuals using weight loss medications such as Ozempic, Wegovy and Zepbound — popular drugs that offer rapid weight loss ...
Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...
Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...
Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results